Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer ...

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

JW Pharmaceutical commercializes CSA test for Hemlibra patients in South Korea JW Pharmaceutical launches a new hemophilia ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with hemophilia A, the most common form of hemophilia. The research team was able to show ...

Every person's hemophilia A journey is different ... s instructions regarding when to use an on demand bypassing agent or ...

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

According to the latest Annual Global Survey by the World Federation of Hemophilia in 2023, there are 809 hemophilia patients in Nepal, with 44 percent of them aged between 19 and 44. Most of these ...

The two drugmakers were working on a treatment for hemophilia in adults. Sangamo said it would explore other options, including finding another partner. Sangamo Therapeutics (SGMO) shares cratered ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...